S042 Coding and Documentation
DESCRIPTION
Speakers in this session review key elements of coding and documentation relevant to the day-to-day practice of clinical dermatologists. Recent or imminent changes in rules and regulations are highlighted. Adequate time is available for numerous questions from the audience.
LEARNING OBJECTIVES
Code E/M visits and procedures correctly.
Apply current rules and guidelines to ensure that chart documentation accurately conveys what occurred and is also adequate to support the codes selected.
Describe recent and impending changes in coding and documentation guidelines.
SCHEDULE
1:00 PM
E/M Made Practical: Documenting to Support Payment
Alexandra Flamm, MD, FAAD
1:30 PM
Teledermatology Coding in 2026 and Beyond: What’s Staying, What’s Changing
Trilokraj Tejasvi, MD, MBBS
2:00 PM
Coding Updates for 2026: What Every Dermatologist Should Know
Howard Wooding Rogers, MD, PhD, FAAD
2:30 PM
Beyond the Graft: Mastering Documentation and Coding for Skin Substitutes
David T. Harvey, MD, FAAD
3:00 PM
Proving Medical Necessity: Essential Documentation for Mohs Surgery
Alexander Miller, MD, FAAD
3:30 PM
Don’t Get Burned: Audit Readiness and Defending Your Dermatology Claims
Faith McNicholas
DIRECTOR
Alexander Miller, MD, FAAD
SPEAKERS
Alexandra Flamm, MD, FAAD
David T. Harvey, MD, FAAD
Anne Arundel Dermatology/ Emory School of Medicine, Department of Dermatology
Faith McNicholas
American Academy of Dermatology Association
Howard Wooding Rogers, MD, PhD, FAAD
Trilokraj Tejasvi, MD, MBBS
HANDOUTS
DISCLOSURES
Alexandra Flamm, MD, FAAD
No financial relationships exist with ineligible companies.
David T. Harvey, MD, FAAD
No financial relationships exist with ineligible companies.
Faith McNicholas
No financial relationships exist with ineligible companies.
Alexander Miller, MD, FAAD
No financial relationships exist with ineligible companies.
Howard Wooding Rogers, MD, PhD, FAAD
Biofrontera AG – Consultant (1099 relationship)(Fees);
Trilokraj Tejasvi, MD, MBBS
No financial relationships exist with ineligible companies.